{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:27:41Z","timestamp":1791412061529,"version":"4.3.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40264-019-00887-2","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T07:03:08Z","timestamp":1579762988000},"page":"243-253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database"],"prefix":"10.1007","volume":"43","author":[{"name":"The French Network of Pharmacovigilance Centres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7482-3331","authenticated-orcid":false,"given":"Thomas","family":"Berbain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Miremont-Salam\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Grandvuillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Chouchana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Benkebil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7306-2999","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Th\u00e9ophile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,23]]},"reference":[{"key":"887_CR1","unstructured":"Guideline on good pharmacovigilance practices (GVP). Module IX\u2014Signal management (Rev 1). European Medicines Agency; 2017. https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf. Accessed 18 Apr 2018."},{"key":"887_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","volume":"31","author":"TB Agbabiaka","year":"2008","unstructured":"Agbabiaka TB, Savovi\u0107 J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2008;31:21\u201337.","journal-title":"Drug Saf."},{"key":"887_CR3","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s40264-013-0083-1","volume":"36","author":"H Th\u00e9ophile","year":"2013","unstructured":"Th\u00e9ophile H, Andr\u00e9 M, Miremont-Salam\u00e9 G, Arimone Y, B\u00e9gaud B. Comparison of three methods (an updated logistic probabilistic method, the Naranjo and Liverpool algorithms) for the evaluation of routine pharmacovigilance case reports using consensual expert judgement as reference. Drug Saf. 2013;36:1033\u201344.","journal-title":"Drug Saf."},{"key":"887_CR4","first-page":"111","volume":"40","author":"B B\u00e9gaud","year":"1985","unstructured":"B\u00e9gaud B, Evreux J, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie. 1985;40:111\u20138.","journal-title":"Therapie"},{"key":"887_CR5","unstructured":"France. Minist\u00e8re des solidarit\u00e9s, de la sant\u00e9 et de la famille. Arr\u00eat\u00e9 du 28 avril 2005 relatif aux bonnes pratiques de pharmacovigilance. JORF n\u00b0121 du 26 mai 2005, p. 9087. https:\/\/www.legifrance.gouv.fr\/affichTexte.do?cidTexte=JORFTEXT000000812853. Accessed 16 Apr 2018."},{"key":"887_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00228-013-1486-8","volume":"69","author":"N Moore","year":"2013","unstructured":"Moore N. The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist. Eur J Clin Pharmacol. 2013;69:33\u201341.","journal-title":"Eur J Clin Pharmacol."},{"key":"887_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00002018-200326030-00003","volume":"26","author":"M Hauben","year":"2003","unstructured":"Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf. 2003;26:159\u201386.","journal-title":"Drug Saf."},{"key":"887_CR8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2165\/00002018-200629100-00005","volume":"29","author":"JS Almenoff","year":"2006","unstructured":"Almenoff JS, LaCroix KK, Yuen NA, Fram D, DuMouchel W. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department. Drug Saf. 2006;29:875\u201387.","journal-title":"Drug Saf."},{"key":"887_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40264-016-0405-1","volume":"39","author":"AFZ Wisniewski","year":"2016","unstructured":"Wisniewski AFZ, Bate A, Bousquet C, Brueckner A, Candore G, Juhlin K, et al. Good signal detection practices: evidence from IMI PROTECT. Drug Saf. 2016;39:469\u201390.","journal-title":"Drug Saf."},{"key":"887_CR10","unstructured":"European Medicine Agency. Screening for adverse reactions in Eudravigilance [online]. DEC 2016. Report No.: EMA\/849944\/2016. Inspections, Human Medicines, Pharmacovigilance and Committees Division. https:\/\/www.ema.europa.eu\/en\/documents\/other\/screening-adverse-reactions-eudravigilance_en.pdf. Accessed 03 May 2018."},{"key":"887_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57\u201369.","journal-title":"Stat Methods Med Res."},{"key":"887_CR12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W DuMouchel","year":"1999","unstructured":"DuMouchel W. Bayesian data mining in large frequency yables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53:177\u201390.","journal-title":"Am Stat."},{"key":"887_CR13","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/sim.3586","volume":"28","author":"I Ahmed","year":"2009","unstructured":"Ahmed I, Haramburu F, Fourrier-R\u00e9glat A, Thiessard F, Kreft-Jais C, Miremont-Salam\u00e9 G, B\u00e9gaud B, Tubert-Bitter P. Bayesian pharmacovigilnace signal detection methods revisited in a multiple comparison setting. Stat Med. 2009;28:1774\u201392.","journal-title":"Stat Med."},{"key":"887_CR14","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). International Working Group V. Current challenges in pharmacovigilance: pragmatic approaches. CIOMS, Geneva, Switzerland 2001."},{"key":"887_CR15","unstructured":"Martindale: The Complete Drug Reference. Micromedex Healthcare Series [database online]. Greenwood Village, CO: Truven Health Analytics; 2018. https:\/\/www.micromedexsolutions.com (Subscription required to view). Accessed 16 Aug 2018."},{"key":"887_CR16","volume-title":"Meyler\u2019s side effects of drugs: the international encyclopedia of adverse drug reactions and interactions","year":"2016","unstructured":"Aronson JK, Dukes MNG, editors. Meyler\u2019s side effects of drugs: the international encyclopedia of adverse drug reactions and interactions. 15th ed. Amsterdam: Elsevier; 2016.","edition":"15"},{"key":"887_CR17","unstructured":"Base de Donn\u00e9es Publique du M\u00e9dicament [online]. Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9; 2018. http:\/\/base-donnees-publique.medicaments.gouv.fr. Accessed 03 May 2018."},{"key":"887_CR18","unstructured":"WHO Pharmaceuticals Newsletter [online]. World Health Organization. http:\/\/www.who.int\/medicines\/publications\/newsletter\/en\/. Accessed 03 May 2018."},{"key":"887_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1541-0420.2009.01262.x","volume":"66","author":"I Ahmed","year":"2010","unstructured":"Ahmed I, Dalmasso C, Haramburu F, Thiessard F, Bro\u00ebt P, Tubert-Bitter P. False discovery rate estimation for frequentist pharmacovigilance signal detection methods. Biometrics. 2010;66:301\u20139.","journal-title":"Biometrics."},{"key":"887_CR20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat. 1995;57:289\u2013300.","journal-title":"J R Stat."},{"key":"887_CR21","unstructured":"MedDRA. Maintenance and Support Services Organization. Introductory guide MedDRA version 20.0. Medical Dictionary for Regulatory Activities. https:\/\/www.meddra.org. Accessed 03 May 2018."},{"key":"887_CR22","unstructured":"Guideline on good pharmacovigilance practices (GVP). Module VI\u2014Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). European Medecines Agency; 2017. https:\/\/www.ema.europa.eu\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf. Accessed 18 Apr 2018."},{"key":"887_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40264-014-0204-5","volume":"37","author":"O Caster","year":"2014","unstructured":"Caster O, Juhlin K, Watson S, Nor\u00e9n GN. Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank. Drug Saf. 2014;37:617\u201328.","journal-title":"Drug Saf."},{"key":"887_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1590\/abd1806-4841.20175871","volume":"92","author":"NB de Natividade","year":"2017","unstructured":"de Natividade NB, Felix PAO, Lerer C. Guillain-Barr\u00e9 syndrome in a patient on adalimumab for the treatment of psoriasis. An Bras Dermatol. 2017;92:85\u20137.","journal-title":"An Bras Dermatol."},{"key":"887_CR25","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s10067-013-2272-9","volume":"32","author":"B Alvarez-Lario","year":"2013","unstructured":"Alvarez-Lario B, Prieto-Tejedo R, Colazo-Burlato M, Macarr\u00f3n-Vicente J. Severe Guillain-Barr\u00e9 syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review. Clin Rheumatol. 2013;32:1407\u201312.","journal-title":"Clin Rheumatol"},{"key":"887_CR26","doi-asserted-by":"publisher","first-page":"A78","DOI":"10.1016\/j.neurol.2012.01.195","volume":"168","author":"D Koenig","year":"2012","unstructured":"Koenig D, Borg M, Bayreuther C, Rocher F, Cohen M, Lebrun C. \u0152d\u00e8me papillaire sous clozapine. Rev Neurol. 2012;168:A78.","journal-title":"Rev Neurol."},{"key":"887_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fimmu.2018.00110","volume":"9","author":"S Viel","year":"2018","unstructured":"Viel S, Pescarmona R, Belot A, Nosbaum A, Lombard C, Walzer T, et al. A case of type 2 hypersensitivity to rasburicase diagnosed with a natural killer cell activation assay. Front Immunol. 2018;9:110.","journal-title":"Front Immunol."},{"key":"887_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1526-4610.1994.hed3404237_2.x","volume":"34","author":"M Chiari","year":"1994","unstructured":"Chiari M, Manzoni GC, Van de Geijn EJ. Ischemic optic neuropathy after sumatriptan in a migraine with aura patient. Headache. 1994;34:237\u20138.","journal-title":"Headache."},{"key":"887_CR29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/0002-9378(79)90712-9","volume":"135","author":"L Hahn","year":"1979","unstructured":"Hahn L, Petruson B. The influence of acetylsalicylic acid and paracetamol on menstrual blood loss in women with and without an intrauterine contraceptive device. Am J Obstet Gynecol. 1979;135:393\u20136.","journal-title":"Am J Obstet Gynecol."},{"key":"887_CR30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00296-013-2710-7","volume":"34","author":"E Crickx","year":"2014","unstructured":"Crickx E, Marroun I, Veyrie C, Le Beller C, Schoindre Y, Bouilloud F, et al. DPP4 inhibitor-induced polyarthritis: a report of three cases. Rheumatol Int. 2014;34:291\u20132.","journal-title":"Rheumatol Int."},{"key":"887_CR31","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.2337\/dc06-0703","volume":"29","author":"P Aschner","year":"2006","unstructured":"Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632\u20137.","journal-title":"Diabetes Care."},{"key":"887_CR32","first-page":"673","volume":"51","author":"ML Ambrosio","year":"2014","unstructured":"Ambrosio ML, Monami M, Sati L, Marchionni N, Di Bari M, Mannucci E. GLP-1 receptor agonist-induced polyarthritis: a case report. Acta Diabetol. 2014;51:673\u20134.","journal-title":"Acta Diabetol."},{"key":"887_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1365-2141.2006.06455.x","volume":"136","author":"E Vichinsky","year":"2007","unstructured":"Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136:501\u20138.","journal-title":"Br J Haematol."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00887-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-019-00887-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00887-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T15:14:12Z","timestamp":1722352452000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-019-00887-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,23]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["887"],"URL":"https:\/\/doi.org\/10.1007\/s40264-019-00887-2","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,23]]},"assertion":[{"value":"23 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to assist in the preparation of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Thomas Berbain, Antoine Pariente, Ghada Miremont-Salam\u00e9, Aur\u00e9lie Grandvuillemin, Joelle Micallef, Laurent Chouchana, Mehdi Benkebil and H\u00e9l\u00e8ne Th\u00e9ophile have no conflicts of interest that are directly relevant to the content of this study. The data used for this study from BNPV and VigiBase<sup>\u00ae<\/sup> are anonymous, and are used in agreement with the CRPVs responsible for managing this data and in compliance with the conditions of use elaborated for this data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}